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Mucopolysaccharidosis VII (MPS VII) is a lysosomal storage disease arising from mutations in β-D-glucuronidase
(GUSB), which results in glycosaminoglycan (GAG) accumulation and a variety of clinical manifestations including
neurological disease. Herein, MPS VII dogs were injected
intravenously (i.v.) and/or intrathecally (i.t.) via the cisterna
magna with AAV9 or AAVrh10 vectors carrying the canine
GUSB cDNA. Although i.v. injection alone at 3 days of age
resulted in normal cerebrospinal ﬂuid (CSF) GUSB activity,
brain tissue homogenates had only ~1 to 6% normal GUSB
activity and continued to have elevated GAG storage. In
contrast, i.t. injection at 3 weeks of age resulted in CSF
GUSB activity 44-fold normal while brain tissue homogenates had >100% normal GUSB activity and reduced GAGs
compared with untreated dogs. Markers for secondary storage and inﬂammation were eliminated in i.t.-treated dogs
and reduced in i.v.-treated dogs compared with untreated
dogs. Given that i.t.-treated dogs expressed higher levels
of GUSB in the CNS tissues compared to those treated i.v.,
we conclude that i.t. injection of AAV9 or AAVrh10 vectors
is more effective than i.v. injection alone in the large animal
model of MPS VII.
Received 20 May 2015; accepted 22 September 2015; advance online
publication 10 November 2015. doi:10.1038/mt.2015.189

INTRODUCTION
Mucopolysaccharidosis type VII (MPS VII; Sly syndrome) is
a rare lysosomal storage disorder arising from mutations in the
β-glucuronidase gene (GUSB) and is inherited in an autosomalrecessive manner.1,2 The GUSB enzyme is involved in the stepwise
degradation of dermatan, heparan, and chondroitin sulfates, and
its dysfunction results in the accumulation of these glycosaminoglycans (GAGs).3 Clinical manifestations are more severe in MPS

VII patients with little or no residual GUSB activity and include
intellectual disability, hydrocephalus, hepatosplenomegaly, coarse
facial features, dysostosis multiplex, heart valve disorders, and
corneal clouding.1,4 Although intellectual disability is a hallmark
of central nervous system (CNS) involvement, the underlying
cause of cognitive impairment in MPS VII patients is not well
understood. Chronic inflammation of the brain is thought to play
a substantial role in many lysosomal storage disorders with CNS
involvement including the mucopolysaccharidoses.5,6 In MPS VII,
impaired autophagy associated with GAG storage and the secondary accumulation of GM2 and GM3 gangliosides generate cellular
stress that induces an aggressive inflammatory response leading to
a cascade of degenerative processes.5
Few approved clinical therapies exist for the treatment of
MPS VII. Hematopoietic stem cell transplantation of allogeneic
normal cells or gene-modified autologous cells has reduced neurological symptoms in lysosomal storage disorder patients but
still requires a conditioning procedure.7,8 Intravenous enzyme
replacement therapy has recently been developed for MPS VII9–11
but will probably not prevent neurological disease due to the
blood–brain barrier. Although direct CNS delivery with enzyme
replacement therapy is currently being pursued in clinical trials
for other types of MPS (clinical trials identifier #: NCT02060526,
NCT00884949), recombinant enzyme can only provide a shortterm effect, and repeated injections into the CNS will most likely
be required. In contrast, gene therapy could provide long-term
constitutive expression of a therapeutic gene and its protein product after a single dose. However, enzyme levels in brain were only
6% of normal in previous gamma retroviral-vector studies in neonatal MPS VII dogs that resulted in transduction of liver and high
serum GUSB activity after intravenous (i.v.) administration.12,13
Similarly, systemic injection of other vectors has not been very
efficient at preventing storage in the murine brain (reviewed in
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Ponder and Haskins14). Therefore, it is likely that delivery to the
brain will be necessary to achieve an optimal effect.
Recently, adeno-associated viral (AAV) vectors with capsid
proteins from serotype AAV9 and AAVrh10 (rh10) have demonstrated the ability to enter the brains and to transduce neurons and
glia of animals following i.v. injection,15–25 intrathecal (i.t. injection into the cerebrospinal fluid (CSF) via the lateral ventricle or
the cisterna magna, or direct brain parenchyma injections.15,18,23–28
However, a direct comparison of the efficacy of different serotypes
given i.v. or i.t. has not been performed in canines, and the effect
on a canine model of disease has not been determined. Therefore,
our study aimed to discover the distribution of AAV-mediated
GUSB expression in the CNS of dogs with naturally occurring
MPS VII due to a missense mutation (R166H),29 and the effects on
CNS lesions following i.v. and/or i.t. delivery using AAV serotypes
AAV9 and rh10. This study demonstrates that i.t. is superior to i.v.
delivery in MPS VII dogs, but i.v. injection is still able to reduce
some biochemical and histochemical markers of disease.

RESULTS
Intravenous and intrathecal AAV9 and rh10 vectors
were well tolerated
MPS VII dogs were treated with AAV vectors as detailed in Table 1
and as described in the Materials and Methods. Animals designated
as “i.v.-only” received i.v. injection of vector at 3 days of age, “i.t.only” dogs received i.t. injection of vector via the cisterna magna at
3 weeks of age, and “i.v.+i.t.” dogs received i.v. injection of one vector
at 3 days, and i.t. injection of the alternate vector at 2 months of age.
CSF protein and cell counts were determined at 9 days postinjection
and again at the end of the study period and were within normal limits for all dogs (data not shown). All dogs were negative for anticapsid
antibodies to AAV9 and rh10 in both serum and CSF at the start
of the study (Supplementary Tables S1 and S2; Day 0). All treated
dogs generated antibodies against the serotype used for treatment,
which were much higher in serum than CSF regardless of the route of
administration (Supplementary Table S1). Cross-reactive responses
were also noted in serum in single-serotype treated dogs. Intriguingly,
anticapsid antibodies found in the CSF of all i.t.-treated dogs did not
indicate cross-reaction, and higher responses were observed against
the rh10 than the AAV9 capsid (Supplementary Table S2).

Supraphysiological GUSB activity was found in CSF of
i.t.-injected MPS VII dogs
All i.v.-only dogs had CSF GUSB activity ~1.7-fold normal at 6
months postinjection (Figure 1a, red circles), and activity was
relatively stable over the study period. In contrast, i.t.-only dogs
had >250-fold normal CSF GUSB activity (normal CSF mean
~10.7 U/ml) at peak expression, approximately 7 days postinjection (Figure 1a, blue squares). Activity declined slowly, resulting
in average CSF GUSB activity of ~45-fold normal (445 ± 254 U/
ml) and ~42-fold normal (419 ± 151 U/ml), for AAV9 and rh10,
respectively, at the end of the study. There were no differences
between AAV9 and rh10 for i.t.-only dogs in levels of CSF activity
or stability of expression (data not shown). i.v.+i.t.-treated dogs
exhibited a slightly higher CSF activity at 6 months, with 137- and
81-fold normal levels for i.v.-AAV9+i.t.-rh10 and i.v.-rh10+i.t.AAV9, respectively (Figure 1a, green diamonds). It is well known
that circulating enzyme modified with mannose 6-phosphate
(M6P) can be taken up by the M6P receptor on cells.30 The measured percentage of phosphorylated active CSF GUSB enzyme in
the i.t.-only dogs was 40.8 ± 8.1%, which was not significantly different from values in normal dogs at 64.9 ± 4.6%.
Serum GUSB activity was also determined. Following i.v.
injections, GUSB activity was ~30% of normal at 6 months of age
in i.v.-only dogs. In contrast, serum GUSB activity of i.t.-only
dogs was only ~1.7% of normal activity (Figure 1b). i.v.+i.t.injected MPS VII dogs had ~12% of normal serum GUSB activity (Figure 1b).
Normal GUSB activity and reduced GAG storage was
found in the nervous tissue of i.t.-treated dogs
CNS tissue was harvested from all treated dogs at 6 months of age
and biochemical assays performed on homogenates for GUSB
activity, GAG levels, and total HEX activity. These data were
compared with untreated MPS VII and normal control tissues.
i.v.-only dogs had low GUSB activity in brain with <2% normal
activity in the frontal, temporal, and occipital lobes and hippocampus (Figure 1c, top row, red circles). In comparison, i.t.-only
dogs had average GUSB activity in cerebrum that was >95% of
normal activity (Figure 1c, top row, blue squares). Deeper structures such as the hippocampus (195% normal) and brainstem

Table 1 Study design and injection scheme of MPS VII dogs with recombinant AAV vectors
First injection
Animal ID#

Group ID

Agea (days)

ROI

Dose (GC/kg)

Second injection
AAV serotype

Age (days)

ROI

Dose (GC/kg)c

AAV serotype

Gender

AAV9

−

−

−

−

M

rh10

−

−

−

−

F

M2686

i.v.-only

3

i.v.

2 × 10

M2689

i.v.-only

3

i.v.

2 × 1013

M2729

i.t.-only

18

i.t.

12

AAV9

−

−

−

−

F

M2757

i.t.-only

20

i.t.

12

5 × 10

AAV9

−

−

−

−

M

M2760

i.t.-only

20

i.t.

5 × 1012

AAV9

−

−

−

−

M

12

13

5 × 10

M2739

i.t.-only

24

i.t.

5 × 10

rh10

−

−

−

−

M

M2755

i.t.-only

20

i.t.

5 × 1012

rh10

−

−

−

−

F

M2685

i.v.+i.t.

3

i.v.

2 × 10

13

AAV9

70

i.t.

2.8 × 10

M2688

i.v.+i.t.

3

i.v.

2 × 1013

rh10

70

i.t.

5 × 1012

12

rh10

F

AAV9

M

a

Age in days at time of injection.
−, not injected; F, female; GC/kg, vector genome copies per kilogram; i.t., intrathecal; i.v., intravenous; M, male; ROI, route of injection.
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a

b

CSF
i.v. i.t.

i.v. i.t.

GUSB (U/ml)

1,000
100
10

i.v.-AAV9
i.v.-rh10
i.t.-AAV9
i.t.-rh10
i.v.-AAV9 + i.t.-rh10
i.v.-rh10 + i.t.-AAV9
MPS VII
Normal

100

10

1

1
0

50

100

150

200

0

50

Age (days)

GUSB (U/mg)

c

Frontal

i.t.

1,000

10,000
GUSB (U/ml)

Serum

i.t.

Temporal

Occipital

100

150

200

Age (days)
Hippocampus Cerebellum

Brainstem

Cervical

Thoracic

Lumbar

Sciatic nerve

1,000
100
10
1

GAG (μg/mg)

100
10
1

HEX (U/mg)

10,000

n/d

n/d

i.t
i.v .
.+
i.t
.

i.t
i.v .
.+
i.t
.
i.v
.

i.t
i.v .
.+
i.t
.
i.v
.

i.t
i.v .
.+
i.t
.
i.v
.

i.t
i.v .
.+
i.t
.
i.v
.

i.v
.

i.t
i.v .
.+
i.t
.

i.t
i.v .
.+
i.t
.
i.v
.

i.t
i.v .
.+
i.t
.
i.v
.

i.t
i.v .
.+
i.t
.
i.v
.

i.t
i.v .
.+
i.t
.
i.v
.

i.v
.

1,000

Figure 1 Circulating GUSB activity and biochemical analysis of nervous tissue. Nine MPS VII dogs were injected i.v.-only, i.t.-only, or i.v.+i.t. with
AAV9 or rh10 vectors expressing the canine GUSB cDNA as detailed in Table 1. (a,b) CSF and serum were tested for GUSB activity at the indicated
ages. Data are shown for individual animals except for i.t.-only dogs, where the means are plotted for each serotype (i.t.-AAV9, n = 3; i.t.-rh10, n = 2).
The average value in normal dogs ± 1 SD is shown as a horizontal gray bar (n = 9), while untreated MPS VII dogs had <1 U/ml of GUSB activity (data
not shown). Early CSF time points were not collected for i.v.-treated animals. (c) CNS tissues and peripheral nerve were collected at 6 months of age
and tested for GUSB activity, GAG level, and HEX activity. The means of duplicates are recorded for individual animals for all assays, and the means of
duplicates ± 1 SD are indicated with error bars for all i.t.-only dogs (n = 5; data for AAV9 and rh10 were pooled together). Values for normal dogs ±
1 SD (gray-thatched horizontal bars, n = 3 to 9) and untreated MPS VII dogs (yellow horizontal bars, n = 3 to 7) are shown for each tissue. Black bars
indicate the mean for each group. Arrows above the graph indicate when AAV-injections were given in reference to age and are as follows: i.v.-AAV
(black arrow) at 3 days of age for i.v.-only and i.v.+i.t. dogs, i.t.-AAV (blue arrow) at 21 days of age for i.t.-only dogs, and i.t.-AAV (green arrow) at
70 days of age for the i.v.+i.t. dogs. Statistical analysis was performed as indicated in Materials and Methods. Values in other groups were compared
with those in untreated MPS VII dogs, and *P = 0.01–0.05; **P = 0.001–0.01; ***P < 0.001.

(125% normal) also had elevated activity levels for i.t.-only dogs,
which was not surprising given the close proximity of these
structures to the ventricles and surrounding CSF. Results from
i.v.+i.t. dogs resembled those found in i.t.-only dogs (Figure 1c,
top row, green diamonds).
An increase in GAG concentration is a hallmark of the MPS
disorders.12 To assess a therapeutic benefit, total GAG was measured. i.v.-only dogs had elevated GAGs compared to normal
dogs (Figure 1c, middle row), which was significant in the frontal lobe (P < 0.001), temporal lobe (P = 0.002), and brainstem
(P = 0.006) and was not significantly lower than untreated MPS
VII dogs in any region evaluated. In contrast to i.v.-only dogs,
all CNS tissue collected from i.t.-only dogs exhibited lower
GAG levels than untreated MPS VII dogs, which was significant

208

in the frontal (P < 0.001) and temporal (P = 0.004) lobes,
the hippocampus (P = 0.004), and the brainstem (P = 0.007)
(Figure 1c). However, GAGs in i.t.-only dogs still remained elevated compared to normal dogs in most brain tissues and was
significantly higher compared to normal in the frontal lobe (P
= 0.004). Again, results in i.v.+i.t.-treated dogs resembled those
of i.t.-only dogs.
Elevation of other lysosomal enzymes such as HEX is another
hallmark of MPS. Intriguingly, total HEX activity was reduced
in the frontal, temporal, and occipital lobes for the i.v.-only dogs
(Figure 1c, bottom row, red circles; P < 0.001 for all regions) and
thus appeared to serve as a sensitive correlate for low levels of
GUSB activity. HEX activity was also reduced in the i.t.-only and
i.v.+i.t. dogs.
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GUSB activity is widely distributed in the cerebrum of
i.t.-injected MPS VII dogs
To examine the distribution of enzyme activity, a histochemical
GUSB activity stain was used. Normal dogs had diffuse activity
throughout the cerebral cortex (Figure 2a,b) with activity found
in the soma of cortical neurons (Figure 2c, solid arrowhead),
while untreated MPS VII dogs were devoid of GUSB activity
(Figure 2d–f). Both i.v.-only dogs had rare cortical neurons with
substantial GUSB activity, which likely represented transduced
cells (Figure 2g–l), but their frequency was estimated to be only
~0.1%. GUSB activity was also identified in the leptomeninges.
In contrast, i.t.-only dogs displayed widespread GUSB activity in cerebral gray matter (Figure 2m,p). Staining extended
into all layers of the cerebral cortex (layers I–VI) with intense
focal activity in large pyramidal neurons (Figure 2n, o, q, and r).
Transduction of neurons, likely in layer V, was more extensive
in the i.t.-rh10 dogs (Figure 2n,q, black arrows) than for the i.t.AAV9 dogs, which is shown for several regions of the cortex in
Supplementary Figure S1. GUSB staining in the i.v.+i.t. dogs
(Figure 2s–x) resembled that of i.t.-only dogs. Supplementary
Figures S2–S7 demonstrate that GUSB activity in the cortex is
similar among the lobes evaluated and shows global activity for all
of the treated dogs.
Considering the importance of restoring function to all
regions of the brain, deeper sections of the brain were also
Normal

analyzed for GUSB activity, as shown in Supplementary
Figures S8–S10. i.v.-only dogs had detectable GUSB activity
in the caudate nucleus (Supplementary Figure S8), the midbrain near the aqueduct (Supplementary Figure S9), the crus
cerebri (Supplementary Figure S9), and CA3 neurons of the
hippocampus (Supplementary Figure S9). In the brainstem
(Supplementary Figure S10), neuronal cell bodies positive for
GUSB activity were scattered throughout gray matter, although
specific nuclei were not identified. In addition, i.v.-only dogs had
GUSB activity in the choroid plexus (Supplementary Figure
S10), and along axons in the white matter (Supplementary
Figure S10). The i.t.-only dogs had similar GUSB activity as the
i.v.-only dogs in the caudate, midbrain near the aqueduct, brainstem, choroid plexus, and white matter, but clearly had much
higher GUSB activity in the optic tract, crus cerebri, and hippocampus (Supplementary Figures S8–S10).

GUSB activity in the cerebral cortex was associated
with reduced storage of secondary compounds and
reduced inﬂammatory cell inﬁltrate
The accumulation of undegraded metabolites in many of the
MPS disorders is associated with persistent activation of the
lysosomes, astrogliosis, and inflammation.5 To assess preliminary therapeutic effects of AAV-mediated GUSB expression on
storage material, sections of cerebral cortex were analyzed for

MPS VII

i.v.-AAV9

i.v.-rh10

d

g

j

b

e

h

k

c

f

i

l

40×

1×

0.25×

a

i.t.-AAV9

i.v.-AAV9
i.t.-rh10

i.t.-rh10

i.v.-rh10
i.t.-AAV9

p

s

v

n

q

t

w

o

r

u

x

40×

1×

0.25×

m

Figure 2 GUSB stain of cerebral cortex. (a-x) Frozen sections of cerebrum from level R3 (Supplementary Figure S1) were stained for GUSB activity (red color) for samples collected at 6 months of age from animals treated as detailed in Table 1. The boxes in the top rows indicate the region
shown at ×1 magniﬁcation, and the arrow in the middle rows indicate the region shown at higher power in the lower rows (at ×40). Scale bars are
indicated.
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GM3 ganglioside, lysosomes, astrocytes, and microglia (Figure
3). GM3 ganglioside is a secondary storage material that accumulates in MPS VII brains31 and is apparent at 6 months of age
in untreated MPS VII dogs (Figure 3b). Notably, low levels of
GUSB enzyme in i.v.-only dogs were associated with a qualitative reduction in GM3 in cortical neurons (Figure 3c,d). In
contrast, i.t.-only dogs showed near-complete resolution of
GM3 ganglioside accumulation (Figure 3e,f). The intensity of
LIMP2-positive vesicles was reduced in both i.v.- and i.t.-only
dogs compared to those found in untreated MPS VII tissue, indicating reduced lysosomal distension (Figure 3g–l). Astrogliosis
in the cortex was markedly increased in untreated MPS VII dogs
as shown by increased staining for GFAP (Figure 3n). i.v.-only
dogs showed a reduced intensity in GFAP staining (Figure 3op),
while i.t.-only and i.v.+i.t. dogs were similar to normal control
dogs (Figure 3m,q,r). Microglia (Iba1-positive cells) are still
present in treated dogs (Figure 3u–x) but appear to be reduced
compared to untreated MPS VII tissue (Figure 3t). Some Iba1positive cells are present in normal animals (Figure 3s). Cerebral
cortex staining for i.v.+i.t. dogs mirrors those patterns seen in
GM3

LIMP2

GFAP

lba1

g

m

s

b

h

n

t

c

i

o

u

d

j

p

v

e

k

q

w

f

l

r

x

i.t.-rh10

i.t.-AAV9

i.v.-rh10

i.v.-AAV9

MPS VII

Normal

a

Figure 3 Secondary storage, astrogliosis, and inﬂammatory
responses are reduced in treated MPS VII cerebral cortex. Secondary
storage was analyzed in cerebral cortex at 6 months of age by immunohistochemical staining in normal, untreated MPS VII (MPS VII), or MPS
VII dogs that were treated with AAV vector of the indicated route and
serotype. Staining was performed for a secondary storage ganglioside
GM3 (a–f) lysosomal compartments were identiﬁed with lysosomal integral membrane protein LIMP2 (g–l) astrocytes were identiﬁed with glial
ﬁbrillary acidic protein (GFAP) (m–r) and microglial cells were identiﬁed with ionized calcium-binding adapter molecule 1 (Iba1) (s–x). Not
all tissues were stained simultaneously, and many groups only had one
dog, but normal and untreated control samples were performed for all
batches of stains and appeared similar.
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i.t.-only dogs, and no serotype-specific differences were apparent (data not shown).

Purkinje cells exhibit GUSB activity in AAV-treated
MPS VII dogs
Cerebellar sections of a normal dog reveal diffuse GUSB activity in the molecular layer, Purkinje cells (PC), granular cell layer,
and cerebellar white matter (Figure 4a,b). In stark contrast, MPS
VII-affected dogs have no visible GUSB activity staining in the
cerebellum (Figure 4c,d). Both i.v.-only dogs displayed sparse,
focal activity in PCs and limited expression in the white matter
(Figure 4e–h). i.t.-only dogs exhibited greatly enhanced expression
throughout the cerebellar cortex (Figure 4i–l). The histochemical
data correlate well with biochemical data, as GUSB activity was
very high in the cerebellum at 3.1-fold normal in i.t.-only dogs, but
only 0.03-fold normal in i.v.-only dogs (Figure 1c). Similar patterns were observed for the i.v.+i.t.-injected dogs (Figure 4m–p)
as for the i.t.-only dogs.
High-level GUSB activity found in the spinal cord of
all treated dogs and sciatic nerve of i.t.-treated dogs
GUSB stain of spinal cord is shown in Figure 5. Untreated MPS
VII dogs exhibited no GUSB activity throughout the spinal cord.
i.v.-only dogs exhibited high-level GUSB activity throughout the
gray matter, including strong focal staining in lower motor neurons of the ventral horn, regardless of the AAV serotype. This
correlated with biochemical GUSB activity throughout the spinal
cord ranging from 15% at the cervical cord to 59% at the lumbar
cord (Figure 1c, top row). GUSB activity was also seen throughout the dorsal columns that house ascending sensory pathways.
However, GAGs were elevated in the spinal cord in i.v.-only dogs
compared with normal levels (Figure 1c; top versus middle row),
which was significant in the thoracic (P < 0.001 versus normal, not
significant versus untreated MPS VII) and the lumbar (P = 0.01
versus normal, not significant versus untreated MPS VII) spinal
cord. Elevated GAGs may be due to the absence of GUSB activity
throughout the rest of the spinal cord (Figure 5). i.t.-only dogs
had similar GUSB activity with histochemical staining in the
lower motor neurons and dorsal columns as did i.v.-only dogs,
but i.t.-only dogs also had positive GUSB staining in the lateral
and ventrolateral funiculi. Biochemical GUSB analysis revealed
>98% normal activity throughout the spinal cord. This diffuse
GUSB activity may explain why GAGs were lower in the spinal
cord of i.t.-only dogs compared with untreated MPS VII dogs,
which reached significance in the thoracic (P < 0.001) and lumbar
(P = 0.04) regions (Figure 1c).
i.v.+i.t. dogs had strong staining in the dorsal columns and
lower motor neurons, as expected since i.v.-only dogs were positive in these regions. i.v.+i.t. dogs also had strong staining in
the lateral corticospinal tract area (Figure 5, descending motor
tracts), which was different from i.v.-only dogs. However, i.v.+i.t.
dogs had relatively low levels of staining in the other regions of the
spinal cord compared with i.t.-only dogs. There were no obvious
differences in GUSB activity patterns between the two serotypes
tested in this study.
Finally, the sciatic nerve also had enhanced levels of GUSB activity staining in i.t.-only dogs (Supplementary Figure S11), which

www.moleculartherapy.org vol. 24 no. 2 feb. 2016

Official journal of the American Society of Gene & Cell Therapy

AAV Gene Therapy in CNS of Canine MPS VII

Normal
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Low power

a

i.t.-AAV9

i.v.-AAV9
i.t.-rh10
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i.t.-AAV9
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m

o
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l

n

p

High power

Low power

i

Figure 4 GUSB activity in the cerebellum. Cerebellar sections collected at 6 months of age from normal, untreated MPS VII, or MPS VII dogs that
were treated with AAV vectors of the indicated route and serotype were stained for GUSB enzyme activity (red color). The region indicated with a box
at low power is shown at high power below it. GUSB-positive Purkinje cells (PC) soma are indicated in some panels. The granular cell layer (GCL) and
molecular layer (ML) are indicated. Scale bars are indicated.

correlated with the biochemical GUSB data determined at 34% normal (Figure 1c). GUSB staining was noted in myelin sheaths and
potentially axons of the sciatic nerve (Supplementary Figure S11).
Sciatic nerve samples were not collected from other groups.

Biodistribution identiﬁes higher copy numbers in
nervous tissue of i.t.-injected dogs
Vector copy numbers were determined with quantitative PCR
on DNA extracted from tissues (Supplementary Figure S12).
Low copy numbers were found in brain tissue of the two i.v.-only
dogs (mean = 0.01 vector genomes/diploid genome (vg/dg)).
Conversely, all i.t.-treated dogs had 100-fold higher average copy
numbers in brain tissue (mean = 1 vg/dg), and similar values were
identified among the different serotypes. In the spinal cord, vector copy numbers averaged >70-fold higher for i.t.-only compared
with i.v.-only dogs. Systemic copy numbers were found at moderate to low levels for most tissues in all treated groups, with liver tissue having the highest copies. Here, average liver copies were 0.43
vg/dg for i.v.-only dogs and 0.13 vg/dg for i.v.+i.t. dogs. Despite
the fact that vector was only delivered to the CNS, vector was also
detected in liver in i.t.-only dogs at 0.07 vg/dg; vector was also
identified in heart, lung, kidney, and spleen for the i.t.-only dogs.
These data are consistent with the low serum GUSB activity found
in the i.t.-only dogs (Figure 1b).
Intravenous AAV reduces storage in non-CNS tissues
None of the groups had a significant reduction in urine GAGs at
6 months of age compared with values in untreated MPS VII dogs
(Figure 6a). However, i.v.-only dogs had a significant reduction
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in GAGs of the liver and renal medulla, and in HEX activity of
liver, spleen, heart, and renal medulla (Figure 6b). In contrast,
i.t.-only dogs did not have significant reductions in GAGs or total
HEX in any somatic tissue that was analyzed (Figure 6b). Values
in i.v.+i.t. dogs resembled those in i.v.-only dogs. GUSB activity
staining confirmed the presence of active enzyme in liver and
myocardium, confirming that biochemical activity was not due to
blood contamination (Supplementary Figure S13). Thin sections
indicated an absence of storage in liver and spleen of all i.v.-only
and i.v.+i.t. dogs, with a partial reduction of storage lesions in i.t.only dogs (Supplementary Figure S14).

Clinical outcome in treated dogs
Although behavioral abnormalities have been documented in
MPS VII mice, cognitive deficits have yet to be characterized in
the canine model due to difficulties inherent in behavioral testing performed in animals with limited mobility due to orthopedic
disease.32,33 However, gait was evaluated in the treated dogs. While
untreated MPS VII dogs were unable to stand or walk by 6 months
of age (Supplementary Video S1), both i.v.-only dogs retained
the ability to walk, albeit with mild (M2689) to moderate (M2686)
gait abnormalities characterized by a shortened stride length and
increased hock (tarsal joint) flexion of the hindlimb. The i.v.treated dog M2689 could also run. Three of five i.t.-only dogs
(M2729, M2760, and M2739) were able to walk, although each
showed markedly abnormal hock flexion and none could run, and
M2755 and M2757 could not stand. Both i.v.+i.t. dogs (M2685
and M2688) were able to run. Shortened stride length and excessive hock flexion may be due to either joint/orthopedic disease
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MPS VII

i.v.-AAV9

i.v.-rh10

i.t.-AAV9

i.t.-rh10

i.v.-AAV9
i.t.-rh10

i.v.-rh10
i.t.-AAV9

Cervical
spinal cord

Descending motor tracts
Dorsal
column

Lumbar
spinal cord

Thoracic
spinal cord

Descending
motor tract

Dorsal
column

Lower motor
neurons

Lower motor neuron

Figure 5 GUSB activity of the spinal cord. Frozen sections from the cervical, thoracic, and lumbar spinal cord of animals of the indicated groups
were stained for GUSB activity (red color). Some regions of the cervical spinal cord were further imaged at higher magniﬁcation to show the motor
neuron pools (blue arrow), dorsal column (green arrow), and descending motor tracts from the lateral funiculus (purple arrow) as indicated. All cord
segments were oriented in the same direction with dorsal at the top and ventral at the bottom. Scale bars are indicated.

or peripheral nervous system dysfunction. No clear advantage
among serotypes was seen.

DISCUSSION
I.V.-only MPS VII dogs have low GUSB expression in
the CNS
I.V.-only MPS VII dogs received i.v. injection of 2E13 GC/kg
of AAV vectors at day 3 of age, which resulted in limited GUSB
expression by histochemical stains in cortical and hippocampal
neurons, and Purkinje cells, while average expression levels in
other brain tissues were only ~1 to 6% of normal with quantitative assays of homogenates. Enzyme activity for the AAV9-treated
dog was similar to that of the rh10-treated dog, although the small
number of animals (N = 1) would make it difficult to identify small
differences in efficacy. Higher doses were not given due to limited
vector quantities. Our results differ from a study that reported very
high (30% of normal) expression of N-acetylglucosaminidase-α
in nonhuman primate CNS tissue after i.v. administration of an
AAV9 vector,34 although quantification in this other study was
confounded by the background enzyme activity present in these
normal animals. Several other studies in nonhuman primates support our result that i.v. administration is not very efficient in large
animals.15,20,28 It is also possible that accumulation of GAGs in the
endothelium of blood vessels may inhibit the ability of AAV9 vectors to cross the blood–brain barrier, as has been seen in MPS
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VII mice.35 However, this phenomenon has yet to be established
in the MPS VII dogs. Although CNS GUSB activity was low and
CNS GAG levels were not reduced in i.v.-only dogs, lysosomal
HEX activity was normalized, and there was a reduction in GM3,
LIMP2, GFAP, and Iba1 staining in the cortex. These results demonstrate that relatively low levels of enzyme can indeed reduce
markers of disease in the MPS VII brain, which is consistent
with previous studies in MPS VII dogs with a gamma retroviral
vector.13,36
In the spinal cord, motor neurons were clearly transduced
in i.v.-only dogs, which is consistent with the relatively efficient
transduction of motor neurons with AAV9 and rh10 vectors after
i.v. injection.15,16,21,37 There was a progressive increase in GUSB
activity from the cervical to the lumbar region of the spinal cord
for unclear reasons, as has been noted in other studies.16,23

i.t.-only dogs have widespread GUSB activity in CNS
tissues
i.t.-only dogs received 5E12 GC/kg of vector at 3 weeks of age via
the cisterna magna, which resulted in supraphysiological expression throughout the brain and spinal cord. Histochemical staining
revealed GUSB activity in neurons as deep as 2 mm from the surface of the cortex and in Purkinje cells, while quantitative enzyme
assays reported near-normal GUSB levels in CNS tissues at 6
months of age. Enzyme activity was also high in neurons of the
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Figure 6 Systemic biochemical data. Samples were collected at 6 months of age. (a) Urine GAGs were normalized to the amount of creatinine in the
sample using a dye-based binding assay. (b) Samples from liver, spleen, heart, and renal cortex (Renal C) and renal medulla (Renal M) were homogenized and tested for GUSB activity (top row), GAG levels (middle row), and HEX activity (bottom row). The means of duplicates are recorded for all
assays for individual i.v.-only or i.v.+i.t.-treated dogs, while averages are shown for i.t.-only dogs ±1 SD (n = 5). Normal values ± 1 SD (gray-thatched
horizontal bars, n = 9) and values for untreated MPS VII dogs ± 1 SD (yellow horizontal bars, n = 7) ranges are shown in all graphs. Values in the indicated
groups were compared with values in untreated MPS VII dogs as detailed in Materials and Methods. *P = 0.01–0.05; **P = 0.001–0.01; ***P < 0.001.

hippocampus and unidentified nuclei of the brainstem, and these
transduced neurons may transport enzyme to other parts of the
brain via their axons. There was no significant difference in activity between AAV9 and rh10-treated dogs in quantitative GUSB
assays. Although it appeared that the rh10 serotype might result
in better transduction of neurons in Layer V of the cortex than the
AAV9 serotype, too few dogs were evaluated to be conclusive, and
both serotypes resulted in transduced cells in the deeper layers.
Hinderer et al.27 also found high expression using an i.t.-AAV9
vector, which generated fivefold normal α-l-iduronidase levels in
the CNS of a feline model of Hurler syndrome.
Although GUSB activity was near normal in all regions studied and storage was eliminated in the cortex of i.t.-only dogs as
assessed by GM3 and LIMP2 stain, total GAG levels were not
normalized throughout the nervous system tissues. It is likely that
some regions of the brain may fail to achieve sufficient enzyme
activity to eliminate GAG accumulation. Indeed, this study showed
that the caudate nucleus and some other deep regions had relatively low GUSB activity with histochemical stains. Furthermore,
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some regions of the cortex and cerebellum were transduced less
efficiently than other regions of the same tissue for individual dogs,
which may relate to the ability of CSF to freely diffuse to the surface
of a particular region. We are currently performing more detailed
histochemical evaluations to determine if there are regions that
accumulate storage. This study also showed that astrogliosis
(GFAP) and activation of microglial cells (Iba1) was eliminated in
the cortex of i.t.-only dogs. We are currently testing if reduction of
these markers is seen throughout all areas of the brain.
i.t.-only dogs had high GUSB activity throughout the spinal
cord, and a reduction in GAG levels compared with untreated
MPS VII dogs. Transduction of lower motor neurons was likely
responsible for the enzyme activity seen in some axons of the sciatic nerve, while activity in the surrounding myelin sheaths could
be due to uptake from neurons that secrete enzyme or to direct
transduction of Schwann cells; further studies will need to differentiate between these possibilities. Overall, i.t.-only and i.v.+i.t.
dogs had much higher activity in the spinal cord white matter
tract regions than did i.v.-only dogs. Although specific areas were
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not identified, the areas with high enzyme activity likely include
the lateral corticospinal tract containing axons from motor neurons of the cortex, and possibly the rubrospinal tract containing
axons from neurons of the red nucleus in the midbrain for i.v.+i.t.only dogs, while i.t.-only dogs had diffuse staining throughout the
spinal cord white matter with higher activity at the edges of the
tissue, coinciding with ascending tracts.

Effects of i.v.+i.t. treatment
This study showed that a single i.t. injection of either an AAV9 or
rh10 vector at 3 weeks of age produced high levels of GUSB activity in the CSF and neuronal tissues of MPS VII dogs, but relatively
low levels in serum, and only three of five i.t.-only dogs could walk
at 6 months. In contrast, i.v. injections at 2 days of age resulted
in greater systemic GUSB expression than i.t. administration, and
both i.v.-only treated dogs could run at 6 months. In an attempt
to treat both systemic and neurological disease, two dogs received
both i.v. (at day 3) and i.t. (at 2 months with the other serotype)
injections of AAV. Transduction still occurred in the CNS, and
indeed, CSF GUSB in the i.v.+i.t. dogs was slightly higher after the
6-month study period in comparison to the i.t.-only dogs. This
may relate to the older age and larger body size when treated at
2.3 months of age, leading to the total vector particles administered that was threefold that used for the i.t.-only group treated at
3 weeks of age. Here, the i.v.+i.t. group benefited from dual treatment, as the CNS values mimicked the i.t.-only dogs’ GUSB levels
and conversely, peripheral tissue values mirrored those seen in
i.v.-only dogs and both dogs maintained mobility throughout the
study. Peripheral tissue correction levels were also nearly identical
in i.v.-only and i.v.+i.t. dogs, indicating that later i.t.-injections had
no adverse effects on peripheral activity after i.v.-AAV injections.
Although a slight reduction in urine GAGs was seen in i.v.-treated
dogs, overall urine GAG levels were not corrected in any treatment group. Indeed, even high GUSB serum levels in RV-treated
dogs failed to completely correct urine GAGs.38 Similar vector
copy numbers were also identified in all of the CNS tissues tested
among i.t.-only and i.v.+i.t. groups (Supplementary Figure S12)
indicating the feasibility of i.t. injections after i.v. administration
if a different serotype is used. These data support that whole body
correction may be obtained with i.v.+i.t. treatments using different AAV vectors, although more detailed studies on peripheral
tissues need to be done to establish the extent of improvement.
Expression is relatively stable in CSF for six months
In this study, i.v.-treated dogs had relatively stable GUSB activity
at near-normal levels in CSF for six months, which is likely due to
transduction of ependymal cells of the choroid plexus, with a possible contribution from transduced neurons. Similarly, i.t.-only
dogs had relatively stable GUSB activity, although the level was
much higher at 44-fold normal, expression from leptomeningeal
cells probably occurred, and the contribution from neurons was
much higher. Since dogs reach maturity at 6 months, and there
is little replication in the adult brain, expression from the AAV
vectors will likely be maintained long-term after i.t. administration. Indeed, we have now followed one dog for 16 months after
i.t. injection and observed stable expression in the CSF (BL Gurda
and ME Haskins, unpublished data).
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Conclusions
In this study, we demonstrate that i.t. injection of recombinant
AAV9 and rh10-serotyped vectors results in ~50-fold higher expression and a more profound effect on markers of disease than does
treatment with the same vector given i.v.. Although i.v. administration was less efficient, it still reduced a secondary lysosomal enzyme
and markers of astrogliosis and neuroinflammation and may exert
a beneficial effect on neurological function, an aspect that was not
studied here. In disease models with low therapeutic target levels,
i.v.-only injections could potentially provide sufficient delivery to
the CNS to achieve a therapeutic effect. However, in the case of MPS
VII where high tissue activity is necessary, it appears that i.t. injections will be necessary for efficient treatment in the CNS. Overall,
the therapeutic outcome and preliminary safety profiles generated
here support further studies to advance AAV gene therapy for MPS
VII and other CNS disorders into a clinical setting.

MATERIALS AND METHODS
Animals, AAV vector injections, and CSF collections. The MPS VII
dog colony is maintained at the National Referral Center for Animal
Models of Human Genetic Disease at the School of Veterinary Medicine
of the University of Pennsylvania. All protocols were approved by the
Institutional Animal Care and Use Committee (IACUC) of the University
of Pennsylvania. For i.t. injections via the cisterna magna, the suboccipital
region of propofol-anesthetized animals was punctured with a 22 gauge
spinal needle. Following collection of 1–2 ml of CSF by gravity, 1–2 ml of
vector in 0.9% sterile saline was injected over 1–2 minutes. Intravenous
injections (1–2 ml volumes over 1–2 minutes) were performed via the
cephalic vein. Treated dogs were sampled weekly for the first month and
then monthly for the remainder of the study. For repeated CSF collections,
dogs were anesthetized with propofol and 0.5–1 ml of CSF was collected
by gravity flow from the cisterna magna as detailed above. After all procedures, the animals were visually monitored closely over the next 48 hours.
At the end of the study (6 months of age) euthanasia was performed with
an i.v. overdose of pentobarbital (>80 mg/kg).
Treatment groups and study design. Animals designated “i.v.-only”

received an i.v. injection of AAV9 (dog M2686) or rh10 (dog M2689)
at 3 days of age. Animals designated “i.t.-only” received an i.t. injection
of AAV9 (dogs M2739, M2757, and M2760) or rh10 (dogs M2729 and
M2755) at 3 weeks of age. Animals designated “i.v.+i.t.” received i.v. injection of one vector at 3 days of age and i.t. injection of the alternate vector at
2.3 months of age as detailed in Table 1. No adverse events were identified
after i.v. or i.t. injection. Animals were euthanized at 6 months of age.
Vector production. The vector genome encoded AAV2 i.t.Rs flanking a
transcription unit containing the canine cDNA of GUSB29 under the control of a chicken β-actin promoter. The promoter used contained the cytomegalovirus enhancer with the β-actin promoter and a synthetic intron,
which are 100% identical with nucleotide 721–2454 of Genbank39 accession number GI:388594935. The i.t.Rs were from AAV2 and are 100%
identical with nucleotide 4660 to 4493 of GI:209616 (ref. 40). The plasmid was cross-packaged by the Institute of Human Gene Therapy at the
University of Pennsylvania into AAV9 (ref. 41) and rh10 (ref. 42) capsids
resulting in two recombinant viral vectors each containing the same singlestranded AAV2-genome, and large-scale vector preparations were generated as previously described.41
Neutralizing antibody titers. Neutralizing antibody assays were performed on Huh7 cells as previously described.43 Assays on CSF samples
used sterile PBS as a transduction control. The lowest dilution for the assay
was usually 1:5 for serum and CSF, although some samples began with a
1:10 dilution due to low sample volume.
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DNA extraction and biodistribution studies. Total DNA from tissues was

extracted using a QIAamp DNA Mini Kit (Qiagen, Valencia, CA) and from
ethylenediaminetetraacetic acid–treated blood samples using the QIAamp
DNA Blood Mini Kit (Qiagen) following the manufacturer’s recommended protocol. Real-time PCR (TaqMan Universal Master Mix; Applied
Biosystems, Foster City, CA) was used to detect and quantify vector genomes
in total DNA extracted from frozen samples as previously described,44 using
primer and probe sets targeted to sequences within the nRBG polyadenylation signal (forward primer 5′-GCCAAAAATTATGGGGACAT-3′,
reverse
primer
5′-ATTCCAACACACTATTGCAATG-3′,
probe
6FAM-ATGAAGCCCCTTGAGCATCTGACTTCT-TAMRA).
Tissue processing and protein determination. Tissue were homogenized

as detailed in the Supplementary Materials and Methods section in sample buffer (0.9% NaCl, 0.2% Triton), and the supernatant of the lysate was
used for protein, enzyme, and GAG assays.
Enzyme assay. Five to ten microliters of tissue homogenate, serum, or CSF

was incubated in 200 μl of total volume with the appropriate substrate for
1 to 3 hours at 37 °F, and the reactions stopped with 2 ml of stop buffer
(0.32 mol/l of glycine, 0.2 mol/l of sodium carbonate, pH 10.5) as detailed
in the supplemental methods. The fluorescence of the product (4-methylumbelliferyl (4-MU)) was measured with the VersaFluor Fluorometer
(Bio-Rad) at an excitation wavelength of 365 nm and an emission wavelength of 450 nm. The enzyme activity was calculated from the standard
curve of the 4-MU product of the reaction, with 1 unit defined as 1 nmole
of substrate converted to product in 1 hour at 37 °F.
Glycosaminoglcyan assays. Tissue GAGs were assessed using the Blyscan
sulfated GAG assay (Biocolor, Carrickfergus, Antrim, UK) using the manufacturer’s suggested protocol with chondroitin-4-sulfate as the standard
(Sigma, St Louis, MO). Depending on the tissue origin and genotype, 10 to
50 μl of homogenate were assayed. The final value was calculated using the
standard curve and normalized to protein concentration.
Mannose phosphorylation levels on GUSB. Soluble cation-independent
mannose 6-phosphate receptor was coupled to affinity column media as
previously described,45 and samples were applied to an equilibrated column, washed, and eluted with M6P as detailed in the Supplementary
Materials and Methods. GUSB activity in unbound and bound fractions
was determined using 4MU-β-glucuronide fluorescent substrate. These
values were then used to calculate the percentage of mannose phosphorylation on GUSB enzyme.
Tissue preparation and histology. Whole brain and spinal cord were
extracted immediately following euthanasia. The brain was sectioned in
the coronal plane into left and right hemispheres. Five transverse sections
were evaluated from the frontal lobe (R0; Supplementary Figure S1) to
the occipital lobe (R5). Pieces from the right hemisphere were frozen in
optimal cutting temperature embedding media for cryosectioning, and
sections were fixed and stained for GUSB activity as previously described46
using an overnight incubation followed by a nuclear counterstain with
methyl green from Vector Labs (Burlingame, CA). Sections from the left
hemisphere were used for biochemistry and DNA copy analysis after flash
freezing in liquid nitrogen as detailed above. Pieces from the cerebral lobes
and the cerebellum contained some underlying white matter. Other pieces
from the left hemisphere were used for immunohistochemistry.
For GM3 immunohistochemistry, brain slices were fixed overnight in
4% paraformaldehyde/PBS, equilibrated sequentially in 15 and 30% sucrose,
and frozen in optimal cutting temperature embedding medium. GM3
immunostaining was performed as previously described27 using mouse
monoclonal antibody DH2 (Glycotech, Gaithersburg, MD) followed by
a biotinylated secondary antimouse antibody (Jackson Immunoresearch,
West Grove, PA) and detection with a Vectastain Elite ABC kit (Vector Labs).
For immunostaining with GFAP, LIMP2, and Iba1, sections were fixed
in formalin and embedded in paraffin, and 6-μm samples were treated for
Molecular Therapy vol. 24 no. 2 feb. 2016
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antigen retrieval as detailed.27 Primary antibodies used were rabbit antibodies
against GFAP (glial fibrillary acidic protein; used at 1:1,000; Abcam Ab7260,
Cambridge, MA) and LIMP2 (lysosomal integral membrane protein-2 used
at 1:200; Novus Biologicals NB400-129, Littleton, CO), and goat antibody
against Iba1 (ionized calcium-binding adaptor molecule 1; used at 1:100;
Abcam Ab5076). Fi.t.C- or TRi.t.C-labeled donkey antirabbit or antigoat
(Jackson Immunoresearch) served as secondary antibody. Samples used for
thin sections were fixed and embedded in plastic as detailed27 and 1-μm
sections were stained with toluidine blue.
Statistics. Values in different groups were compared using ANOVA with

Holm–Sidak post hoc analysis if normality and equal variance tests passed,
and with ANOVA on ranks with Dunn’s post-hoc analysis if those tests
failed. *P = 0.01–0.05, **P = 0.001–0.01, ***P < 0.001. A P value of <0.05
was considered significant.

SUPPLEMENTARY MATERIAL
Figure S1. Diagram of brain sectioning technique and examples of
GUSB staining from different regions of the cerebral cortex for i.t.treated MPS VII dogs.
Figures S2. GUSB stain at 6 months of age at level R0 (cranial).
Figures S3. GUSB stain at 6 months of age at level R1 (just cranial to
temporal lobe).
Figures S4. GUSB stain at 6 months of age at level R2.
Figures S5. GUSB stain at 6 months of age at level R3.
Figures S6. GUSB stain at 6 months of age at level R4.
Figures S7. GUSB staining at 6 months of age at level R5 (occipital lobe).
Figure S8. GUSB stain of the caudate nucleus.
Figure S9. GUSB stain of the midbrain and hippocampus.
Figure S10. GUSB stain of the brainstem, choroid plexus, and white
matter.
Figure S11. GUSB stain of sciatic nerve in i.t.-only treated dogs.
Figure S12. Biodistribution in AAV-treated MPS VII tissues.
Figure S13. GUSB stain of liver and left myocardial free wall (heart).
Figure S14. Thin sections of liver and spleen.
Table S1. Neutralizing antibody titers against AAV9 and AAVrh10 capsids in serum.
Table S2. Neutralizing antibody titers against AAV9 and AAVrh10 capsids in CSF.
Video S1. Subjective mobility observations in AAV-treated MPS VII dogs.
Materials and Methods
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